Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 161   

Articles published

MRK 60.11 +0.11 (0.18%)
price chart
3 Reasons Merck & Co., Inc.'s Stock Could Fall
If you were lucky enough to time your purchase of Merck (NYSE: MRK ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater.
Related articles »  
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 18
Shares of Merck & Co. Inc. led all laggers on the Dow Monday with a decline of 0.32%. The DJIA closed at 16,838.70, which is a 1.06% change from the previous day's close.
Related articles »  
Merck & Co. Inc. (MRK) Tops DJIA Gainers for August 22
The Dow closed at 17,001.20 on Friday, which is a -0.22% move from yesterday's close. Merck & Co. Inc. led all gainers with a 0.54% jump.
Company Update: Merck & Co Inc (NYSE:MRK) � [video] Merck & Pfizer team up
Summary (NYSE:MRK) : Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on August 21
Shares of Merck & Co. Inc. led all laggers on the Dow Thursday with a decline of 1.06%. The DJIA closed at 17,039.60, which is a 0.36% change from the previous day's close.
Why Wall Street Is Not Bearish On Merck
None of the analysts covering Merck & Co., Inc. (MRK) are bearish due to the company's strong drug pipeline. However, many are not completely sure of Merck's future and have a neutral stance on the pharmaceutical.
Wednesday's Analyst Moves: Pfizer Inc., Merck & Co., Inc., Bristol-Myers ...
Deutsche Bank has initiated coverage on Eli Lilly and Co (LLY ) with a �Buy� rating and a $71 price target. This price target suggests an 11% increase from the stock's current price.
Related articles »  
3 Reasons Merck & Co., Inc.'s Stock Could Rise
For investors lucky enough to have jumped into Merck in 2009 at the tail end of the Great Recession you've seen an appreciation in your shares of near 100%.
Related articles »  
5 Things Merck & Co., Inc.'s Management Wants You to Know
In its second-quarter earnings results, released just two weeks ago, Merck reported a 1% decline in worldwide sales to $10.9 billion from the year-ago period, weighed-down by patent expirations and increasing competition, as its adjusted earnings per ...
Related articles »  
Merck & Co., Inc. (MRK): The Grand Daddy of Pharma
Right now, Merck & Co., Inc.(NYSE:MRK), this nation's second biggest pharmaceutical maker, is a curious animal: a value stock that's priced like a growth stock.